Have a personal or library account? Click to login
Resensitization of Fluconazole-Resistant Urinary Candida spp. Isolates by Amikacin through Downregulation of Efflux Pump Genes Cover

Resensitization of Fluconazole-Resistant Urinary Candida spp. Isolates by Amikacin through Downregulation of Efflux Pump Genes

Open Access
|Mar 2020

References

  1. Aktas E, Yigit N, Ayyildiz A. Esterase activity in various Candida species. J Int Med Res. 2002 Jun;30(3):322–324. https://doi.org/10.1177/147323000203000315
  2. Alenezy AK. Candiduria in diabetic patients in Arar Northern Area, Saudi Arabia. Life Sci J. 2014;11(1):366–370.
  3. Alfouzan WAM. Epidemiological study on species identification and susceptibility profile of Candida in urine. Fungal Genom Biol. 2015;05(02):124. https://doi.org/10.4172/2165-8056.1000124
  4. Alhussaini MS, El-Tahtawi NF, Moharram AM. Phenotypic and molecular characterization of Candida species in urine samples from renal failure patients. Sci J Clin Med. 2013;2(1):14–25. https://doi.org/10.11648/j.sjcm.20130201.13
  5. Alkilani AA, El Shalakany AH, Saif WYM. Candiduria in catheterized Menoufia patients: emerging microbiological trends. Menoufia Med J. 2017;30:892–898.
  6. Ashour SM, Kheiralla ZM, Maklad SS, Ameen MR, Zaki SS. Relationship between virulence factors of Candida species with candiduria and myeloperoxidase concentrations. Int J Curr Microbiol Appl Sci. 2015;4(1):108–123.
  7. Awad ET, Mohamad EA. The use of chrom agar for detection of Candida albicans and non-albicans nosocomial infections of immunocompromised patients in Shebin El-Kom teaching hospital: risk factors and an analysis of microbiological data. Egypt J Med Microbiol. 2014 Jul;23(3):37–45. https://doi.org/10.12816/0024350
  8. Bukhary ZA. Candiduria: a review of clinical significance and management. Saudi J Kidney Dis Transpl. 2008 May;19(3):350–360.
  9. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother. 2004 Jun 01;48(6):2124–2131. https://doi.org/10.1128/AAC.48.6.2124-2131.2004
  10. Chiem K, Jani S, Fuentes B, Lin DL, Rasche ME, Tolmasky ME. Identification of an inhibitor of the aminoglycoside 6′-N-acetyltransferase type Ib [AAC(6′)-Ib] by glide molecular docking. Med Chem Comm. 2016;7(1):184–189. https://doi.org/10.1039/C5MD00316D
  11. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved guideline M27-A3. Wayne (USA): Clinical and Laboratory Standards Institute; 2008.
  12. da Silva CR, de Andrade Neto JB, Sidrim JJC, Ângelo MRF, Magalhães HIF, Cavalcanti BC, Brilhante RSN, Macedo DS, de Moraes MO, Lobo MDP, et al. Synergistic effects of amiodarone and fluconazole on Candida tropicalis resistant to fluconazole. Antimicrob Agents Chemother. 2013 Apr;57(4):1691–1700. https://doi.org/10.1128/AAC.00966-12
  13. Deorukhkar SC, Saini S, Jadhav PA. Evaluation of different media for germ tube producation of Candida albicans and Candida dubliniensis. Int J Biol Adv Res. 2012 Sep 26;3(9):704–707. https://doi.org/10.7439/ijbar.v3i9.732
  14. Fankam AG, Kuiate JR, Kuete V. Antibacterial and antibiotic resistance modifying activity of the extracts from Allanblackia gabonensis, Combretum molle and Gladiolus quartinianus against Gram-negative bacteria including multi-drug resistant phenotypes. BMC Complement Altern Med. 2015 Dec;15(1):206. https://doi.org/10.1186/s12906-015-0726-0
  15. Fekete-Forgács K, Gyüre L, Lenkey B. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses. 2000 Sep;43(7–8):273–279. https://doi.org/10.1046/j.1439-0507.2000.00587.x
  16. Fotedar R, Al-Hedaithy SSA. Comparison of phospholipase and proteinase activity in Candida albicans and C. dubliniensis. Mycoses. 2005 Jan; 48(1):62–67. https://doi.org/10.1111/j.1439-0507.2004.01057.x
  17. Goyal R, Sami H, Mishra V, Bareja R, Behara R. Non-albicans candiduria: an emerging threat. J Appl Pharm Sci. 2016;6(3):048–050. https://doi.org/10.7324/JAPS.2016.60308
  18. Hasan F, Xess I, Wang X, Jain N, Fries BC. Biofilm formation in clinical Candida isolates and its association with virulence. Microbes Infect. 2009 Jul;11(8–9):753–761. https://doi.org/10.1016/j.micinf.2009.04.018
  19. Hassaneen AM, Ghonaim RA, Hassanin HM, Salama NA, El Gohary T. Different aspects of candiduria as an important nosocomial infection. Med J Cairo Univ. 2014;82(1):199–204.
  20. Höfs S, Mogavero S, Hube B. Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota. J Microbiol. 2016 Mar;54(3):149–169. https://doi.org/10.1007/s12275-016-5514-0
  21. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofilms and drug resistance. Emerg Infect Dis. 2004 Jan;10(1):14–19. https://doi.org/10.3201/eid1001.030119
  22. Jain M, Dogra V, Mishra B, Thakur A, Loomba P, Bhargava A. Candiduria in catheterized intensive care unit patients: emerging microbiological trends. Indian J Pathol Microbiol. 2011;54(3): 552–555. https://doi.org/10.4103/0377-4929.85091
  23. Jia W, Zhang H, Li C, Li G, Liu X, Wei J. The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms. BMC Microbiol. 2016 Dec;16(1):113. https://doi.org/10.1186/s12866-016-0728-1
  24. Kashid RA, Belawadi S, Devi G, Indumati I. Incidence of non-Candida albicans in patients with urinary tract infection with special reference to speciation and antifungal susceptibility. J Evol Med Dental Sci. 2012 Oct 29;1(4):572–577. https://doi.org/10.14260/jemds/89
  25. Kauffman CA. Candiduria. Clin Infect Dis. 2005 Sep 15;41(6) Supplement_6:S371–S376. https://doi.org/10.1086/430918
  26. Kaur R, Dhakad M, Goyal R, Haque A, Mukhopadhyay G. Identification and antifungal susceptibility testing of Candida species: A comparison of Vitek-2 system with conventional and molecular methods. J Glob Infect Dis. 2016;8(4):139–146. https://doi.org/10.4103/0974-777X.192969
  27. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an Overview. Cold Spring Harb Perspect Med. 2016 Jun;6(6): a027029. https://doi.org/10.1101/cshperspect.a027029
  28. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun. 2002 Feb 1;70(2):878–888. https://doi.org/10.1128/IAI.70.2.878-888.2002
  29. Li H, Zhang C, Liu P, Liu W, Gao Y, Sun S. In vitro interactions between fluconazole and minocycline against mixed cultures of Candida albicans and Staphylococcus aureus. J Microbiol Immunol Infect. 2015 Dec;48(6):655–661. https://doi.org/10.1016/j.jmii.2014.03.010
  30. Lu M, Yu C, Cui X, Shi J, Yuan L, Sun S. Gentamicin synergises with azoles against drug-resistant Candida albicans. Int J Antimicrob Agents. 2018 Jan;51(1):107–114. https://doi.org/10.1016/j.ijantimicag.2017.09.012
  31. Mattei AS, Alves SH, Severo CB, Guazzelli LS, Oliveira FM, Severo LC. Determination of germ tube, phospholipase, and proteinase production by bloodstream isolates of Candida albicans. Rev Soc Bras Med Trop. 2013 Jun;46(3):340–342. https://doi.org/10.1590/0037-8682-0045-2013
  32. Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013 Feb 15;4(2):119–128. https://doi.org/10.4161/viru.22913
  33. Mohan Das V, Ballal M. Proteinase and phospholipase activity as virulence factors in Candida species isolated from blood. Rev Iberoam Micol. 2008;25(4):208–210. https://doi.org/10.1016/S1130-1406(08)70050-0
  34. Omar M, Fam N, El-Leithy T, El-Said M, El-Seidi E, El-Etreby T. Virulence factors and susceptibility patterns of Candida species isolated from patients with obstructive uropathy and bladder cancer. Egypt J Med Microbiol. 2008;17:317–326.
  35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001 May 1;29(9):45e–45. https://doi.org/10.1093/nar/29.9.e45
  36. Pongrácz J, Benedek K, Juhász E, Iván M, Kristóf K. In vitro biofilm production of Candida bloodstream isolates: any association with clinical characteristics? J Med Microbiol. 2016 Apr 01;65(4): 272–277. https://doi.org/10.1099/jmm.0.000207
  37. Ramirez M, Tolmasky M. Amikacin: uses, resistance, and prospects for inhibition. Molecules. 2017 Dec 19;22(12):2267. https://doi.org/10.3390/molecules22122267
  38. Rodrigues LB, Santos LR, Tagliari VZ, Rizzo NN, Trenhago G, Oliveira AP, Goetz F, Nascimento VP. Quantification of biofilm production on polystyrene by Listeria, Escherichia coli and Staphylococcus aureus isolated from a poultry slaughterhouse. Braz J Microbiol. 2010 Dec;41(4):1082–1085. https://doi.org/10.1590/S1517-83822010000400029
  39. Sallam SA, Arafa MA, Razek AA, Naga M, Hamid MA. Device-related nosocomial infection in intensive care units of Alexandria University Students Hospital. East Mediterr Health J. 2005 Jan-Mar; 11(1–2):52–61.
  40. Schwalbe R, Steele-Moore L, Goodwin AC. Antimicrobial susceptibility testing protocols. Antifungal susceptibility testing of yeasts. New York (USA): CRC Press; 2007. p. 173–208.
  41. Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. BioMed Res Int. 2013;2013:1–13. https://doi.org/10.1155/2013/204237
  42. Talaat M, Hafez S, Saied T, Elfeky R, El-Shoubary W, Pimentel G. Surveillance of catheter-associated urinary tract infection in 4 intensive care units at Alexandria university hospitals in Egypt. Am J Infect Control. 2010 Apr;38(3):222–228. https://doi.org/10.1016/j.ajic.2009.06.011
  43. Tellapragada C, Eshwara VK, Johar R, Shaw T, Malik N, Bhat PV, Kamath A, Mukhopadhyay C. Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic Candida from blood stream infections and vulvovaginal candidiasis. J Pathogens. 2014;2014:1–8. https://doi.org/10.1155/2014/142864
  44. Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Candida growth in urine cultures: a contemporary analysis of species and antifungal susceptibility profiles. QJM. 2016 May;109(5): 325–329. https://doi.org/10.1093/qjmed/hcv202
  45. Wiebusch L, de Almeida-Apolonio AA, Rodrigues LMC, de Paula Bicudo B, dos Santos Silva DB, Lonchiati DF, de Araujo RP, Grisolia AB, de Oliveira KMP. Candida albicans isolated from urine: phenotypic and molecular identification, virulence factors and antifungal susceptibility. Asian Pac J Trop Biomed. 2017 Jul; 7(7):624–628. https://doi.org/10.1016/j.apjtb.2017.06.006
  46. Yashavanth R, Shiju MP, Bhaskar UA, Ronald R, Anita KB. Candiduria: prevalence and trends in antifungal susceptibility in a Tertiary Care Hospital of Mangalore. J Clin Diagn Res. 2013 Nov; 7(11):2459–2461. https://doi.org/10.7860/JCDR/2013/6298.3578
  47. Ying S, Chunyang L. Correlation between phospholipase of Candida albicans and resistance to fluconazole. Mycoses. 2012 Jan;55(1): 50–55. https://doi.org/10.1111/j.1439-0507.2011.02024.x
DOI: https://doi.org/10.33073/pjm-2020-010 | Journal eISSN: 2544-4646 | Journal ISSN: 1733-1331
Language: English
Page range: 73 - 84
Submitted on: Nov 12, 2019
Accepted on: Feb 6, 2020
Published on: Mar 11, 2020
Published by: Polish Society of Microbiologists
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 EVA A. EDWARD, NELLY M. MOHAMED, AZZA S. ZAKARIA, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.